ORIGINAL RESEARCH article
Front. Oncol.
Sec. Gynecological Oncology
This article is part of the Research TopicEvolving Therapies in Gynecological Oncology: From Chemotherapy to Personalized MedicineView all 7 articles
Predictive value of the KELIM in neoadjuvant treatment for patients with advanced ovarian cancer
Provisionally accepted
- Central Hospital of Dalian University of Technology, Dalian, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: To explore the significance of modeled CA-125 elimination rate constant (KELIM) in predicting satisfactory cytoreduction at interval debulking surgery (IDS), survival prognosis, and platinum-based chemosensitivity in patients with advanced ovarian cancer treated with neoadjuvant chemotherapy followed by interval debulking surgery (NACT-IDS). Methods: The clinical information and follow-up data of 70 patients with advanced ovarian cancer who underwent NACT-IDS in the Department of Gynecology of Dalian Central Hospital from January 2010 to June 2023 were retrospectively analyzed. The KELIM for each patient during neoadjuvant chemotherapy was calculated using the online calculation tool (https://www.biomarker-kinetics.org/CA-125-neo), and its predictive value for IDS surgical outcome, prognosis, and platinum-resistant recurrence (PRR) was analyzed. Results: A total of 70 patients met the inclusion criteria. The median follow-up time was 32 (range 6–116) months. KELIM was an independent factor for predicting satisfactory debulking at IDS. Patients with higher KELIM had a higher probability of achieving satisfactory debulking (1.40 vs. 0.61, P < 0.05). KELIM and IDS surgical outcomes were independent influencing factors for progression-free survival (PFS) and overall survival (OS). The median PFS and OS in patients with KELIM ≥1 were significantly higher than those in patients with KELIM <1 (26 months vs. 18 months, P < 0.05; 39 vs. 28 months, P < 0.05). KELIM ≥1 is an independent protective factor for subsequent recurrence of platinum resistance in patients with NACT-IDS. The median KELIM value of the platinum-sensitive recurrent group was significantly higher than that of the PRR group (1.30 vs. 0.73, P < 0.05). For patients with high KELIM, the risk of PRR is low even if IDS cytoreductive surgery is not satisfactory. Conclusions: KELIM is an important parameter to consider when performing IDS. The KELIM and IDS outcomes are independent predictors of the prognosis and PRR risk of patients with NACT-IDS. Even if cytoreduction is unsatisfactory, patients with high KELIM still have a lower risk of subsequent recurrence of platinum resistance.
Keywords: CA125 KELIM, Advanced ovarian cancer, Neoadjuvant chemotherapy, Interval debulking surgery, chemosensitivity
Received: 31 Jul 2025; Accepted: 18 Dec 2025.
Copyright: © 2025 Wang, Yu, Yuan, Wang, Bian, Yang and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Yongai Yu
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.